Assessed quality of life (LQ) of patients with ankylosing spondylitis (AS) according to the results of the General questionnaire EQ-5D and the SF-36 questionnaire. The patients were divided into 2 groups depending on the basic treatment: 1 group — 16 patients received combination therapy of INF according to the standard scheme and NSAIDs in standard doses, group 2 — 50 patients receiving NSAID monotherapy at standard doses. The measurements were taken at baseline and after 12 months of therapy. Found that health problems have all patients AS. The dynamics of VS (visual scale) questionnaire EQ-5D at 12 months of observation indicates an increase of LQ in patients with AS on the background of combined therapy of IFN and NSAIDs. The change of the health index on the background of combined therapy of IFN and NSAIDs complies with satisfactory therapeutic effect, whereas in the group of patients with NSAID monotherapy is minimal. According to the results of the SF-36 questionnaire found statistically significantly higher rates of vital activity, contributing to mental health patients received combination therapy of INF and NSAIDs.
ankylosing spondylitis, tumor necrosis factor α, the quality of life, questionnaire EQ-5D, questionnaire SF-36
1. Braun J., Bollow M., Sieper J. Radiology and pathology of the spondyloarthropathies. Rheum Dis Clin North Am.1998; 24: 697-735.
2. Sieper J., Rudwaleit M., Baraliakos X. et al. The Assesment of Spondyloarthritis international Society (ASAS) Handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009; 68 (Suppl. II): ii1-ii44.
3. Folomeeva O.M., Galushko E.A., Erdes Sh.F. Rasprostranennost´ revmaticheskikh zabolevaniy v populyatsiyakh vzroslogo naseleniya Rossii i SShA. Nauchno-prakticheskaya revmatologiya. 2008; 4: 4-13.
4. Braun J., Sieper J. Ankylosing spondylitis. Lancet. 2007; 369 (9570): 1379-90.
5. Van der Linden S., van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am. 1998; 24(4): 663-76.
6. Braun J., Pham T., Sieper J. et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003; 62: 817-24.
7. Vorob´ev P.A. Kliniko-ekonomicheskiy analiz. -Moskva. 2004; S. 10-15.
8. Staquet M.J. Quality of life assessment in clinical trials. Oxford University Press. 1998: 360
9. Amirdzhanova V.N., Koylubaeva G.M. Metodologiya otsenki kachestva zhizni v praktike revmatologa. Nauchno-prakticheskaya revmatologiya. 2003; 2: S. 72-6.
10. Dougados M., Paternotte S., Braun J. et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011; 70: 249-51
11. Braun J., Davis J., Dougados M. et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006; 65: 316-20.
12. Van der Linden S., Valkenburg H., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthr Rheum. 1984; 27: 361-8.
13. Ware J.E., Snow K.K., Kosinski M. et al. SF-36 Health Survey. Manuel and Interpretation Guide. Lincoln, RI: Qualitymetric Inc. 2000; 150.
14. Amirdzhanova V.N., Goryachev D.V., Korshunov N.I., Rebrov A.P., Sorotskaya V.N. Populyatsionnye pokazateli kachestva zhizni po oprosniku SF-36. Nauchno-prakticheskaya revmatologiya. 2008; 1: 37-3.
15.
